Posts tagged “Quintiles”
Novan is expanding its management team with a new chief development officer position. The company, which went public last year, also is looking for a new chief financial officer.
Former Quintiles chief executive Tom Pike received $20.6 million in compensation following his post-acquisition departure from the Durham-based clinical research company in late 2016, according to a filing with the Securities and Exchange Commission.
A pair of life science giants - and rivals - are making moves. QuintilesIMS is raising nearly $1.5 billion in capital, perhaps in part for future acquisitions. Meanwhile, LabCorp makes a buy to expand its services network.
The Dow hit the 20,000 mark Wednesday, and other Street benchmarks are at record levels as well as the post-election "Trump bump" continues. Several Triangle tech stocks have joined the surge, but management changes at Quintiles and Red Hat show not even Donald Trump means every stock rises.
Tom Pike is walking away from millions of dollars in stock and bonuses as he retires "effective immediately" from QuintilesIMS. The former Quintiles CEO, who stepped aside as part of a $17 billion merger with IMS, could have made more than $17 million if he had stayed with the life science giant through 2017. Pike isn't talking, according to the company.
Tom Pike, the CEO who led Quintiles to a multi-billion dollar merger earlier this year with IMS and accepted a demotion as part of the deal, is retiring.
QuintilesIMS is the result of a recently completed merger between Quintiles Transnational Holdings Inc. and IMS Health Holdings Inc. The companies reported separate third quarter results. And one of its first acts is a plan to repurchase $1.5 billion worth of shares by the end of 2017,
Over the past two decades, an explosion in biomarker and genomic research has enabled the life science industry to develop 71 drugs that target cancer, according to a new report from the QuintilesIMS Institute. The development of personalized treatment based on genetic information is one example of data's growing importance to improving human health, the report says.
Quintiles has a new name: Quintiles IMS Holdings Inc. after the multi-billion-dollar merger between the two life science companies was officially wrapped up Monday morning. Will there be layoffs? That's note clear right now.
In the $17 billion "merger of equals" between Quintiles and IMS Health, the new QuintilesIMS management tilts to IMS at the highest of three levels but the old Quintiles nabs well over half of the next two executive suite tiers.
John Ratliff, who resigned as president of Quintiles for "personal reasons" in 2013, is taking over as CEO of Covance Drug Development, which is now owned by LabCorp.
IMS Health Holdings will own a majority of shares if and when a proposed merger with Quintiles wins regulatory approval. And that ownership is shown in the lineup of the proposed executive lineup for a new company as Quintiles CEO Tom Pike takes on a lesser role.
The $17 billion merger between Quintiles and IMS Health means more than a new title and responsibilities for Quintiles CEO Tom Pike. One of Quntiles' top executives will leave along with two board members if the deal wins regulatory approval.
A recent survey by Morrisville-baed Worldwide Clinical Trials revealed that 62 percent of respondents are more likely to engage a clinical research organization (CRO) partner for clinical research than they were five years ago. That means business for many NC firms.
Triangle headlines: RTI-Zika research; Quintiles glucose monitoring; Cree's LED plant lights; PatientPay exec; Q2 award
Triangle headline news this week includes: RTI to host Zika research; Quintiles offers new glucose monitoring service; Cree offers new LEDS to boost plants; PatientPay adds a new exec; and Quintiles joint venture Q2 wins an award.
Quintiles aims to speed up development for apps to boost healthcare with a new "Solution Design Studio." The accelerator's team will work with Quintiles clients in a variety of initiatives such as virtual reality and wearables.